In 2023, the Office of the US Trade Representative (USTR) has elected to continue conducting its Special 301 Review process virtually, with no in-person hearing, as in the years prior to 2020. In this virtual process, after stakeholders have submitted… Continue Reading
On April 28, 2022, Knowledge Ecology International (KEI) provided comments on the latest National Institutes of Health (NIH) Federal Register notice concerning licensing, the “Prospective Grant of an Exclusive Patent License: Development of Diagnostic for Imaging and Early Detection of… Continue Reading
Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) on March 16, 2022 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies (CAR-T) That are Specific to… Continue Reading
(Update: The NIH provided a response to our questions and comments on February 28, 2022) On February 9, 2022, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health regarding the “Prospective Grant of Exclusive Patent License: Development… Continue Reading
On Wednesday January 12, 2022, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding a prospective exclusive, sublicensable license to the University of Louisville Research Foundation (ULRF), for “Griffithsin Compositions for Treatment and Prevention of… Continue Reading
(Update: On November 4, 2021, the NIH provided a response to our comments on the license.) On October 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the ““Prospective Grant of an Exclusive… Continue Reading
On September 27, 2021, Knowledge Ecology International (KEI) submitted the following comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent License: Chimeric Live-Attenuated Vaccine for West Nile Virus (WNV)” (86 FR 50722). The technology… Continue Reading
Knowledge Ecology International (KEI) filed comments on July 27, 2021 regarding the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Oligonucleotides Analogues Targeting Human LMNA “lamin A” Gene” (86 FR 36563). The inventions are currently co-owned… Continue Reading
On July 27, 2021, Knowledge Ecology International (KEI) commented on the “Prospective Grant of an Exclusive Patent License: RP2 AAV-Based Gene Human Therapy for Ocular Diseases and Disorders Including XLRP” (86 FR 36565). The National Institutes of Health (NIH) intends… Continue Reading
(Update: The NIH provided the following response on July 30, 2021.) Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health’s (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: High ASS1 Expressing… Continue Reading